Skip Navigation

Cardiovascular Research 2000 48(3):464-472; doi:10.1016/S0008-6363(00)00201-7
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Baron, J. H
Right arrow Articles by Gershlick, A. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baron, J. H
Right arrow Articles by Gershlick, A. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis

Julia H Barona,*, Elena P Moiseevaa, David P de Bonoa, Keith R Abramsb and Anthony H Gershlicka

aDivision of Cardiology, Department of Medicine and Therapeutics, University of Leicester, Leicester, UK
bDepartment of Epidemiology and Public Health, University of Leicester, Leicester, UK

* Corresponding author. Tel.: +44-116-256-3038; fax: +44-116-287-5792

Objectives: Brief intravenous administration of chimeric antibody c7E3 Fab during coronary angioplasty has been shown in some studies to provide long term protection against coronary events. Smooth muscle cell (SMC) adhesion and migration are key initial steps in the development of restenosis. The purpose of this study was to investigate the effect of c7E3 Fab on adhesion and migration of SMC to the extracellular matrix (ECM) proteins osteopontin (Opn) and vitronectin (Vn). Methods: Adhesion of human vascular SMCs to ECM proteins was quantified using a CyQUANT assay kit. Migration of SMCs to Vn, Opn and PDGF was studied using a modified Boyden's chamber migration assay. Integrin expression was determined by immunoprecipitation. Results: c7E3 Fab reduced SMC adhesion on Vn and Opn to 69.2±3.3% (P<0.001) and 52.5±4.8% (P<0.001) respectively, compared to adhesion without antibody present. This reduction was the same as that for anti-{alpha}vβ3 integrin antibody LM609 (P = 0.5). The combination of anti-{alpha}vβ5 integrin antibody and c7E3 Fab had a greater effect than either antibody alone (P<0.001). c7E3 Fab reduced SMC migration to Vn and Opn to 51.6±8.9% (P<0.001) and 20.3±6.1% (P<0.001) respectively, compared to migration in the absence of antibodies. Again, similar results were seen with LM609. PDGF-induced SMC migration was also inhibited by c7E3 Fab (P = 0.004) and LM609 (P = 0.001), but to much less an extent. The migration SMCs from a culture found not to express the {alpha}vβ3 integrin was unaffected by these antibodies, strengthening the argument that c7E3 Fab inhibits SMC function via this integrin. Conclusions: c7E3 Fab inhibits the adhesion and migration of SMCs via the {alpha}vβ3 integrin. The inhibition, however, is partial, and varied depending on type of ECM protein and {alpha}vβ3 integrin expression. Some of the clinical benefits of c7E3 Fab may be due to its effect on SMCs.

KEYWORDS Extracellular matrix; Monoclonal antibodies; Receptors; Restenosis; Smooth muscle


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.